A genetic link between lipid metabolism and inflammation has been suggested by the association between variation in the APOE gene and plasma C-reactive protein (CRP). This association was confirmed among Caucasians and extended to an African-American population, and the well-known associations of APOE variation with LDL-C and apoE protein were also observed. While eight common variants in APOE were examined, the association with CRP involved primarily the two nonsynonymous SNPs that define the major e2, e3, and e4 alleles. In particular, the strongest link involved lower CRP levels among carriers of the APOE e4 allele that also contributes to the risk of cardiovascular and Alzheimer's diseases as well as to higher lipid levels. A lesser effect was characterized by lower CRP levels among carriers of a subtype of the e3 allele. The magnitude of the association with plasma CRP was at least as great as the effect of variation in the CRP gene itself. Quantitative analysis suggested that the effect on CRP is more likely a consequence of intrinsic functional differences among the E2, E3, and E4 apoE proteins than different levels of apoE protein or LDL-C in the plasma.
Introduction
The APOE gene has emerged as one of the most important known genetic determinants of several common diseases, including cardiovascular disease (CVD) [1] [2] [3] and Alzheimer's disease. [4] [5] [6] [7] [8] It encodes apolipoprotein E (apoE) that functions in lipid metabolism and cholesterol transport as a component of chylomicrons and very lowdensity lipoprotein cholesterol (LDL-C) particles. Two common nonsynonymous single nucleotide polymorphisms (SNPs) in the APOE gene specify the major e2, e3, and e4 alleles and encode apoE proteins with altered affinity for the LDL-receptor, an effect that contributes to altered levels of plasma lipids. [9] [10] [11] [12] Thus, compared with apoE E3 protein, apoE E2 has cysteine instead of arginine at residue 158 whereas apoE E4 has arginine instead of cysteine at residue 112. Individuals with the apoE E4 protein have elevated levels of plasma LDL-C and other plasma lipid fractions, both risk factors for CVD. Additional SNPs in the APOE gene influence the level of plasma apoE protein to a lesser extent than the two major variants, 13, 14 and have not been associated with disease. In some populations, the additional variation in the APOE gene further explains variation in the lipid fractions.
14 Although high levels of LDL-C and other lipid fractions have atherogenic properties, inflammatory processes are believed to contribute to the progression of CVD and to the risk of an acute thrombotic event, manifesting as myocardial infarction or stroke. Inflammation is commonly assessed by plasma level of a pentraxin-family protein, C-reactive protein (CRP), that is a component of a highly conserved defense system termed innate immunity. Acute initiating events such as infection can cause an increase in CRP level by over 1000-fold. 15 In the absence of an acute stimulus, baseline CRP levels strongly predict incident CVD. 16, 17 Moreover, CRP levels are minimally correlated with plasma lipid risk factors and add prognostic information for cardiovascular risk across all levels of LDL-C, high density lipoprotein cholesterol (HDL-C), non-HDL-C, apolipoprotein A (apoA), and apolipoprotein B (apoB), and across the spectrum of metabolic syndrome. 16, 18, 19 The degree to which inflammation processes in general or more specifically CRP levels represent direct causes of CVD instead of the body's response to an underlying insult remains a subject of current research. 20, 21 Recent reports have suggested an association between the major APOE alleles and CRP levels, an intriguing observation that may suggest further links among apoE protein, lipid metabolism, inflammatory processes, atherosclerosis, and incident CVD. [22] [23] [24] [25] We evaluated this association and the potential effects of additional APOE genetic variation in three separate prospective populations, including both Caucasian and African-American subgroups. We also examined the influence of APOE genetic variation on apoE protein, and associations among plasma apoE protein, CRP, and LDL-C.
Results
APOE alleles associated with CRP, LDL-C, and apoE protein Among Caucasian PRINCE participants, APOE alleles were associated with plasma CRP level in a manner approximately opposite to their association with LDL-C ( Figure 1 , Table 1a ). CRP levels were generally lower for participants with allele combinations that included APOE e4 and higher for participants with combinations including either e2 or e3 (analysis of variance (ANOVA), P ¼ 4 Â 10
À7
; Figure 1 , left). In contrast, participants with the e2 and e4 alleles had, respectively, lesser and greater levels of LDL-C than subjects with the e3 allele (ANOVA, P ¼ 2 Â 10
À8
; Figure 1 , center). In these same participants, the trend for plasma levels of apoE protein with APOE allele was more similar to the trend for CRP than to the trend for LDL-C (ANOVA, P ¼ 4 Â 10 À22 ; Figure 1 , right). The proportions of the variance explained in (logtransformed) CRP, LDL-C, and (log-transformed) apoE protein by model-free classifications based on the five combinations of APOE alleles observed in the sample were 4.1, 4.9, and 11.5%, respectively.
The association of APOE variation with CRP level in the PRINCE cohort was concordant with associations in two other populations. Among the 497 participants in the Physicians' Health Study examined (PHS, all male, Caucasian, and not currently smoking), [26] [27] [28] the e2 and e3 alleles were linked to higher levels of CRP whereas the e4 allele was linked to lower levels (ANOVA, P ¼ 0.036; Table 1b (lesser significance than in PRINCE may be due to assay method, see Materials and methods)). Similarly, among Caucasian, nonsmoking and non-hormone replacement therapy (HRT) using participants from the Women's Health Study (WHS) who were selected for either high or low plasma CRP, allele combinations containing e2 and e3 were more common in the high CRP group, whereas allele combinations containing e4 were more common in the low CRP group (global w 2 test, Po0.0005; Table 1c ).
Quantitative effects
The magnitudes of the effects of the e2 and e4 alleles on the three biomarkers relative to the levels for the e3 allele were judged by regression under the assumption of an additive genetic model. The decrease in the geometric mean of CRP associated with a single copy of the e4 allele was estimated as a factor of 0.68 (95% CI 0.60-0.77, Po10 À7 ; Table 2a ) the level with two copies of the e3 allele (1.66 mg/dl geometric mean), whereas the increase in the geometric mean for a single copy of the e2 allele was estimated as a nonsignificant factor of 1.12 (95% CI 0.98-1.38). No significant effect of e2 could be detected in comparing the difference in CRP level between only subjects with the e2e3 and the e3e3 allele combinations in PRINCE, supporting the conclusion that any difference between e2 and e3 is small. Among the 83 non-HRT using, nonsmoking African-American participants in the primary prevention cohort of PRINCE, the effect of e4 could be observed too, and was estimated as a factor of 0.54 (95% CI 0.35-0.81, P ¼ 4.2 Â 10 À3 ) times the level for e3 homozygotes (Table 2a) . Adjustment by age, gender, and body mass index (BMI) had little effect on the estimates for the genetic effects but increased their significance in some cases (Table 2a) . Similarly, although there were significant differences in median CRP levels for men and women in the PRINCE cohort, the effects of alleles and gender did not appear to involve epistasis as judged by the lack of significance of an interaction term in the regression models (data not shown).
In the replication cohorts, regression analysis yielded comparable quantitative estimates. Among PHS subjects who were not currently smoking, the effect for e4 was significant and estimated as a factor of 0.74 times (95% CI 0.62-0.88) the level for the e3 homozygous subjects, whereas the effect for e2 was not significant (Table 2a) . Including the smokers, but adjusting for smoking, age, and BMI yielded similar results (Table 2a) . Logistic regression for the nonsmoking WHS participants yielded a significant odds ratio of 0.38 for e4 for subjects in the 'high CRP' group versus the 'low CRP' group compared with e3 homozygote subjects but no significant effect for e2 (Table 2b ). Again adjustment for clinical covariates after including the smokers had little effect on the significance (Table 2b) .
Among the Caucasian PRINCE participants, single copies of the e2 and e4 alleles led to a 13.2 mg/dl decrease (P ¼ 2.6 Â 10
À7
) and a 3.4 mg/dl increase (P ¼ 3.0 Â 10
À2
), respectively, in LDL-C compared with the mean level of 141.5 mg/dl for two copies of the e3 allele. Adjustment by age, gender, and BMI had little effect on the significance of the estimates (Table 2a) . In contrast to the result with CRP where e2 and e3 were more similar to each other than to e4, the regression coefficients indicate that the e4 allele is more similar to the e3 allele than is the e2 allele for the effect on LDL-C.
A single copy of the e2 allele led to a factor of 1.24 times more apoE protein than the level for two copies of the reference e3 allele (4.4 mg/dl geometric mean), whereas a single copy of the e4 allele led to a factor of 0.95 less plasma apoE protein (Table 2a) . Like the association with LDL-C, the effect of e4 relative to e3 was estimated to be less significant than the effect of the e2. Again, adjustment for age, gender, and BMI in the regression model had little effect on the significance of the estimates (Table 2a) .
APOE genetic effects after adjustment for apoE protein level
The apoE proteins encoded by the three different alleles have amino-acid substitutions at two residues, raising the question of whether the associations with CRP and LDL-C are consequences of different biological activities or alternatively effects mediated by the level of apoE protein. This question was addressed with the same regression models as before, by examining potential confounding of the genetic associations by an additional adjustment for apoE protein. For plasma CRP, an association with apoE protein was not significant, and adjustment by apoE protein only slightly altered the significance of the effects of e2 and e4, in the absence or presence of the clinical covariates age, gender, and BMI (Table 2c , fully adjusted analysis not shown). For LDL-C, apoE protein was also not significant as a covariate and had little effect on the significance of the genetics. Similarly, additional adjustment by CRP in the models for LDL-C or by LDL-C in the models for CRP had little effect on the significance of APOE alleles (Table 2b) .
Comparable to the model-free estimates, the proportions of the variance explained in the regression models by the genetic effects of the APOE alleles in PRINCE were 3.5, 3.5, and 6.5% for CRP, LDL-C, and apoE protein, respectively. The combination of genetics and the clinical covariates gender, age, and BMI explained 25.9, 4.1, and 7.1% proportion of the variance, respectively. In models including apoE protein and the clinical covariates along with the genetics, the proportion of variance explained was essentially unchanged for both CRP and LDL-C.
Correlations
Previous reports suggest little or no correlation between CRP and LDL-C, but do not exclude the potential for correlation within particular genetic strata due to the distinct functional properties of the three apoE proteins. 16,19. For Caucasian PRINCE participants, the lack of correlation in the unstratified analysis was recapitulated (Table 3) , with no significant correlation for any of the pairwise combinations of CRP, LDL-C, and apoE protein.
Similarly, within the possible genetic strata defined by pairs of APOE alleles, no significant correlation was found (Table 3) . It should be noted that the three largest coefficients involved the e4 allele and might be found significant in larger samples.
Additional APOE SNPs
Six additional SNPs in the APOE gene with minor allele frequency 41% were examined in the PRINCE population for additional genetic influences on the three biomarkers. 29 Each of the six additional common SNPs was tested by linear regression, one at a time, in additive genetic models that also included the two primary SNPs defining the e2, e3, and e4 alleles. None of the new SNPs was associated with levels of CRP. Nevertheless, two SNPs each were associated with LDL-C (APOE-2, APOE-4) and apoE protein (APOE-3, APOE-8), but not with greater magnitude than for the e2 and e4-determining SNPs alone (Table 4) . C-reactive protein and APOE genetic variation DI Chasman et al Table 2 Estimated effects of APOE e2 and e4 alleles on plasma biomarker concentration Additional APOE haplotypes The additional SNPs provided an opportunity to examine whether common subtypes of the e2, e3, and e4 alleles had distinct associations with CRP, LDL-C, or apoE protein. From the combination of the six new SNPs and the two original primary SNPs, eight haplotypes were inferred with frequency greater than 1% and posterior probability greater than 95%. Global tests of association with all eight haplotypes at once were highly significant (Po0.0001) for all three biomarkers.
As with the initial analysis, the influence of individual haplotypes was assessed by linear regression with the assumption of an additive genetic model that specified the reference haplotype as the most common subtype of e3, e3.a (36.7%; Table 5 ). In general, subtypes of the major alleles had patterns of effects and significance ( Table 5) that were similar to the patterns observed for the major alleles themselves (Table 3) . However, within the e3 clade there appeared to be some heterogeneity with respect to the levels of CRP and apoE protein. The effect of e3.d (frequency 5.2%) on the level of CRP was both statistically different from e3.a and relatively large enough (ratio ¼ 0.71) that it was similar to the effects for the e4 subtypes. For apoE protein, subtype e3.b (frequency 30.0%) was statistically different from the reference subtype e3.a, and the magnitude of its effect (ratio ¼ 0.96) was intermediate between the reference level for the e3.a haplotype and the levels for the e4 subtypes.
Discussion
Our findings support and extend previous observations of an association between genetic variation in APOE and the level of CRP, a biomarker for inflammation and a risk factor for CVD. The major effect was characterized by lower levels of CRP among APOE e4 carriers compared to e2 or e3 carriers. A much smaller and nonsignificant effect was the higher CRP level among APOE e2 carriers compared to e3 carriers. There may be additional heterogeneity within the e3 clade for the association with CRP represented by the e3.d haplotype. At the same time, subjects with APOE e3 had higher levels of LDL-C compared to subjects with APOE e2 and subjects with APOE e4 had higher levels still as has been found in other populations. ApoE protein, which is the product of the APOE gene and a component of LDL-C, was lowest among e4 carriers and highest among e2 carriers. In contrast to the association with CRP, the differences between e3 and e4 alleles in the associations with LDL-C and apoE protein were smaller and less significant than the differences between e3 and e2.
However, functional differences rather than effects mediated through the level of apoE protein between the e4 allele and either e2 or e3 alleles appear to account for the association of APOE with CRP. We were able to draw this conclusion by the lack of confounding or even significance for apoE protein in predicting CRP levels in regression models for the genetic effects. It may be that the amino-acid substitution from cysteine to arginine at residue 112 that characterizes apoE E4 is responsible for relatively lower levels of CRP, and possibly lower levels of inflammation. The association with the major APOE alleles can be related to similar observations in other populations. Two reports describe the association in mostly Caucasian, dyslipidemic patients and report significantly lower levels of CRP among carriers of the e4 allele. 22, 30 A third publication describes the association in subjects undergoing coronary angiography to assess coronary artery disease but who were not necessarily hyperlipidemic, and where the contrast between lower levels of CRP among e4 carriers and higher levels among e2 carriers or e3 homozygotes was significant. 25 As in our study, no significant difference was found between e2 carriers and e3 homozygotes. The fourth study found a significant difference while e2 carriers and e3 homozygotes as well as between e2 and e4 carriers in Japanese-American families, while estimating CRP heritability in this population at about 0.27-0.29 24 .
The contribution of the APOE variants to the variation in plasma CRP is among the largest identified to date, accounting for about 3.5-4.1% of the variance in CRP among Caucasians from the primary prevention population in PRINCE and a slightly smaller 2.4% in the PHS population. For comparison, the same alleles explained about 3.5-4.9% of the variance in LDL-C in the PRINCE population, approximately the same as previous estimates. 3, 31, 32 The contribution of APOE alleles to apoE protein levels was larger, about 6.5-11.5%, again consistent with previous estimates of 8.8-20.0% among Caucasians. 31 The proportion of variance in CRP explained by APOE genetic variation is about the same as the amount explained by common variation in the CRP gene itself. About 2.1 and 4.9%, respectively, of the CRP variation in the PRINCE and PHS populations was explained by common variation of the CRP gene, 28 whereas about 1.6-3.3% of the variation in CRP was explained by common CRP gene variation in other, mostly Caucasian populations. 33 In our data, there was no evidence of an epistatic interaction between APOE and CRP genetic variation in explaining the level of plasma CRP (data not shown). The lack of a correlation between the biomarkers in our data is consistent with previous findings, 16, 19, 34 with the exception of a negative correlation observed in obese adults between CRP and apoE protein. 23 A potential limitation to our conclusions is the possibility for ascertainment bias in the mildly hyperlipidemic and mostly Caucasian PRINCE population. However, we made similar observations in the PHS and WHS populations, neither of which was ascertained on the basis of lipid or CRP levels. The observation of the association among African Americans in PRINCE supports the extension to non-Caucasian populations that was suggested previously by the concordant observations in the study of Japanese Americans. 24 The association of CRP level with APOE variation may reflect physiological differences linked to human evolutionary history, as has been suggested for the increased risk to APOE e4's carriers for cardiovascular and Alzheimer's diseases. 11 In spite of its intermediate frequency, the e4 allele is thought to be the ancestral allele of the APOE locus, having been surpassed in Table 5 Association of subtypes of the e2, e3, and e4 APOE alleles with the three Biomarkers in linear regression analysis frequency by e3, which arose about 150 000-220 000 years ago and has been preserved through positive selection. Other variation at the APOE locus suggests that the e2 allele arose from e3 more recently. 11, [35] [36] [37] As the diseases that are more prevalent among e4 carriers affect primarily older adults, and only on some genetic backgrounds and in some environments, 7, 8 it is thought that the e4 allele may provide a benefit during reproductive years in environmental circumstances associated with ancestral humans. These proposed benefits could have involved emerging roles of apoE protein distinct from its involvement in lipid metabolism, including its participation in neuronal repair, in regulation of the immune response, and in the resistance to infectious disease, a process that involves the conserved and therefore ancient components of innate immunity including CRP. 11, 38 Perhaps the association of APOE genetic variation with CRP level reflects an aspect of an ancestral benefit to human health mediated through an influence of apoE protein on one of these alternative biological processes.
Materials and methods

Subjects
Three independent populations were used in these analyses. The first derived from the Pravastatin Inflammation/CRP Evaluation (PRINCE) that was designed to examine the effects of statin therapy on plasma levels of CRP. 39 For the current study of APOE genetic variation, we limited our analysis of the PRINCE population to 946 individuals who had no prior history of CVD, were Caucasian nonsmokers, and were not using postmenopausal HRT (median age 56 years, median BMI 28.5 lb/ in 2 , 28.1% female, mean LDL-C 142.3 mg/dl, median CRP 1.52 mg/l, median apoE 4.32 mg/dl). An additional 83 PRINCE subjects who were nonsmoking AfricanAmericans not using HRT and had no prior history of CVD (median age 54 years, median BMI 30.4 lb/in 2 , 38.6% female, mean LDL-C 140.6 mg/dl, median CRP 3.4 mg/l) were used to evaluate the association of APOE with CRP and LDL-C in a non-Caucasian group. The second population derived from the Physicians' Health Study (PHS), a prospective cohort of initially healthy American male physicians who were followed over a 20-year period for future vascular events. 40 For this analysis of APOE genotype and CRP, we evaluated a randomly selected subset of 589 Caucasian participants who remained free of CVD during follow-up (median age 59.9 years, median BMI 24.4 lb/in 2 , 15.4% current smokers, median CRP 1.05 mg/l). [26] [27] [28] The third population derived from the WHS, a prospective cohort that included approximately 28 000 initially healthy American women who were followed over a 10-year period for future vascular events. [41] [42] [43] In parallel with the PRINCE analysis, we limited this group to those women of Caucasian origin who were not taking HRT. From these, a 'high CRP' subgroup of 358 women was selected from those with CRP levels above the 85th percentile (45 mg/ l) (median age 52.2 years, median BMI 31.0 lb/in 2 , 17.0% current smokers) and a 'low CRP' subgroup of 359 women was selected from those with CRP levels below the 5th percentile (o0.2 mg/l) (median age 48.9 years, median BMI 21.6 lb/in 2 , 8.1% current smoking). 28 All selected participants from all three studies had both plasma and DNA available for analysis.
Biomarker determinations LDL-C was determined by a homogenous direct method (Roche Diagnostics, Indianapolis, IN, USA). The day-today variation in measurements for LDL-C concentrations of 90, 106, and 129 mg/dl were 3.01, 2.34 and 2.18%, respectively. The concentration of CRP in the PRINCE and WHS populations was determined with a high sensitivity immunoturbidimetric assay (Denka Seiken, Niigata, Japan) as described previously. 16 The day-to-day variability in measurements at concentrations of 0.91, 3.07 and 13.38 mg/l were 2.81, 1.61 and 1.1%, respectively. In the PHS population, a lower sensitivity enzyme-linked immunosorbent assay (ELISA) method was used to determine CRP concentrations. 17 ApoE concentration was determined by an immunoturbidimetric technique (Wako Chemicals USA, Richmond, VA, USA). The day-to-day variability in measurements for apoE concentrations of 2.6, 7.3 and 11.8 mg/dl were 4.2, 3.7 and 3.2%, respectively. All measurements were performed in a clinical laboratory and the interday variability was estimated as part of routine practice with fresh plasma samples. The samples for the current determinations had been stored frozen in liquid nitrogen and the interday variability can be expected to be slightly greater. For example, day-to-day variability in CRP from frozen samples in the same laboratory is typically in the range of 3-4%. The limit of detection of CRP with the high sensitivity assay is about 0.002 mg/l.
SNP selection and genotyping
For the PRINCE cohort, we identified the common variation due to SNPs in the APOE gene from the literature and from resequencing in 35 Coriell (Camden, NJ, USA) cell lines with diverse biogeographic ancestry. 29 Eight of these SNPs had minor allele frequency 41% among Caucasians in PRINCE and were tested for association with CRP, LDL-C and apoE protein. Seven of the eight SNPs have dbSNP identification numbers and, ordered along the chromosome from the 5 0 end of the APOE gene, were: APOE-1 (5 0 end of gene, rs7256173), APOE-2 (5 0 end of gene, rs7259620), APOE-3 (intron 1, rs440446), APOE-4 (intron 2, rs769450), APOE-5 (exon 4, rs429358), APOE-6 (exon 4, rs7412), APOE-7 (3 0 end of gene), and APOE-8 (3 0 end of gene, rs439401). The minor alleles of APOE-5 and APOE-6, respectively, determine the APOE e4 and e2 alleles. Although APOE-7 was not represented in dbSNP it can be identified by a match to the sequence AGACGA GAGCTGGCG[C/A]TCAGAGAGGGGAAGC within the APOE gene. Genotyping was performed using mass spectrometry-based methodology as described elsewhere. 29 Overall, genotypes for the selected SNPs were successfully determined in 498% of the sample. A set of reference markers included with the study samples provided no evidence for inaccurate genotyping calls, and only genotypes for SNP APOE-1 were slightly out of Hardy-Weinberg equilibrium (P ¼ 0.04). For the PHS cohort, genotypes were determined only for APOE-5 and APOE-6 using an immobilized hybridization assay as described previously with a success rate of 499%.
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For the WHS cohort, genotypes at APOE-5 and APOE-6 were determined using the Taqman system (Applied Biosystems) with success in 497.8% of the samples and no evidence of inaccurate genotyping calls.
Haplotype inference and linkage disequilibrium
The e2, e3, and e4 APOE alleles and were inferred directly from genotypes under the assumption that the minor alleles of APOE-5 and APOE-6 never appear in the same haplotype. 31, 37, 44 This assumption was supported in the study populations by statistical inference procedures. All adjacent pairs of SNPs APOE 1-8 were in linkage disequilibrium with D 0 exceeding 0.96. However, linkage correlations between adjacent SNPs measured by r 2 were essentially absent except for APOE-6 and APOE-7 with r 2 ¼ 0.6. Nevertheless, the linkage disequilibrium across the locus was sufficient that haplotypes inferred with the expectation maximization algorithm implemented in the haplo.em routine in the haplo.stats package 45 and through coalescent theory implemented in the program PHASE v.2.1.114 were identical, and could be assigned unambiguously to 495% of the PRINCE subjects with posterior probability exceeding 0.95. Only these subjects with confidently inferred haplotypes were used in the analysis.
Tests of association
Approaches with and without the assumption of a genetic model were used to test the association of APOE variation with the plasma biomarkers. CRP and apoE protein levels had approximately log-normal distributions, and the measurements of these biomarkers were log-transformed for some statistical analyses. To diminish the potential effects of outlying values, subjects (o1% in all cases) with biomarker values exceeding three s.d. from the mean were excluded for computation of effect estimates and P-values. Model-free tests of association were performed with ANOVA comparing the means of the (possibly log-transformed) biomarker levels among groups defined by observed pairs of alleles. For determining the contribution of individual alleles to biomarker levels and investigating the possible influences of clinical factors, an additive genetic model was fit using linear regression. The basic approach treated the most common allele (common haplotype or SNP major allele) as a reference and the number of copies of each alternative allele (e.g. haplotypes or minor alleles of SNPs) as the independent variable. For the e2, e3, and e4 alleles, the additive assumption was justified by its better fit to the data than the alternative dominant or recessive models, and by the lack of an interaction term between e2 and e4 alleles in models assigning the more common e3 as the reference. Effect estimates and significance for the influence of genetics were determined by standard analysis of the corresponding regression coefficients. When exponentiated, the effect estimates for the logtransformed biomarkers (CRP, apoE protein) were interpreted as the ratio of the geometric mean of biomarker concentration between subjects homozygous for the major allele and subjects with a single copy of the minor allele. In the analysis of the genetic effects associated with the classification of WHS subjects into high and low CRP categories, w 2 tests and logistic regression were used instead of ANOVA and linear regression. When exponentiated, logistic regression coefficients were interpreted as odds ratios between the two groups for each copy of the genetic variant with respect to the reference genotype. Global tests of haplotype association were performed with haplo.score. 45 
